nicotinamide mononucleotide has been researched along with Left Ventricular Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; He, B; Huang, R; Wan, Y; Wang, C; Wang, L; Zhu, D; Zhu, J | 1 |
1 other study(ies) available for nicotinamide mononucleotide and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiotonic Agents; Cardiotoxicity; Doxorubicin; Fibrosis; Heart; Inflammasomes; Inflammation; Male; Myocardium; Nicotinamide Mononucleotide; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Rats, Sprague-Dawley; Ventricular Dysfunction, Left | 2021 |